drugset / Trial / NCT06764836
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1/VEGF bispecific antibody fusion protein) + IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody) combination therapy in patients with advanced solid tumors.
Timeline
- Start
- 2024-07-23
- Primary completion
- 2026-01-27
- Completion
- 2026-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM27M | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 10 mg/kg | Intravenous |
| Subject | PALVERAFUSP ALFA | Protein / enzyme biologic | 20 mg/kg | Intravenous |